Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues, net $ 122,621 $ 240,259
Operating expenses:    
Cost of implants and other costs 95,948 81,670
Research and development 4,273,815 1,125,098
Selling, general and administrative 3,167,577 4,565,346
Depreciation and amortization 77,254 29,413
Total operating expenses 7,614,594 5,801,527
Loss from operations (7,491,973) (5,561,268)
Other income (expenses):    
Interest expense, net (510,959) (1,622,426)
Grant income 4,464,626 1,091,061
Loss on sale of fixed assets 0 (1,902)
Other miscellaneous income 31,799 46,214
Total other income (expenses), net 3,985,466 (487,053)
Net loss before provision for income taxes (3,506,507) (6,048,321)
Income taxes 0 0
Net loss (3,506,507) (6,048,321)
Non-controlling interest 34,276 8,691
Net loss attributable to BioCorRx Inc. $ (3,472,231) $ (6,039,630)
Net loss per common share, basic and diluted $ (0.65) $ (1.71)
Weighted average number of common shares outstanding, basic and diluted 5,377,670 3,523,208